Microbiome-based diagnostics and therapeutics
Ended · Israel
Source: EU Funding & Tenders Portal
The problem: Much effort has been directed to identifying disease risk factors and indeed, numerous genetic, lifestyle, anthropometric and clinical risk factors are routinely used for this task. However, the clinical utility of existing risk factors is limited and most of them appear when physiological derangements have already occurred. The gut microbiome plays a role in human physiology and heal
- Status
- Closed
- Sector
- Power Transmission, Power Generation (CCGT)
- Location
- Israel
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Microbiome-based diagnostics and therapeutics
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The problem: Much effort has been directed to identifying disease risk factors and indeed, numerous genetic, lifestyle, anthropometric and clinical risk factors are routinely used for this task. However, the clinical utility of existing risk factors is limited and most of them appear when physiological derangements have already occurred. The gut microbiome plays a role in human physiology and health and as such, combining it with existing risk factors can lead to earlier and more robust disease detection. However, very few microbiome-based markers predictive of disease onset and progression were found to date and none are currently used by healthcare systems. The solution: In the ERC-funded project, we used our unique multi-omics and longitudinally profiled 10,000-person cohort and biobank to develop methods for metagenome-wide association studies. We found microbial genetic variation at the single nucleotide level and single bacterial genes level whose baseline levels were predictive of future disease onset. In this ERC-PoC, we propose to prioritize the bacteria found in the ERC-funded project (WP1) and use them within machine learning disease diagnostic models (WP2) that we will then license to diagnostic companies. We further propose to build a microbial biobank of the ERC-identified strains by isolating them from cohort participants, functionally characterizing them with metabolomics and combining them into bacterial consortiums (WP3). As these strains have therapeutic potential, we will license them to probiotic or pharmaceutical companies (WP4). Notably, we already validated this approach in two licensing agreements, one with a Japanese-based company who licensed bacteria that we found for treating Atopic Dermatitis, and another with a U.S. based probiotics company who licensed bacteria that we found for weight loss. If successful, our ERC-PoC may thus result in novel microbiome-based diagnostic and therapeutic products for various disease indications. |
Location
Country | Israel |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Power Transmission, Power Generation (CCGT) |
Article published date | 2025-10-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Power Transmission projects in Israel
- Tzafit GasFired Power Plant
- Cost-effective rehabilitation of public buildings into smart and resilient nano-grids using storage
- Realizable Advanced Cryptography
- WATERSIGN: Smart Water Monitoring & Leakage Detection
- High-Voltage Micro-Photovoltaic Cells and Photodetectors Based on Guided Nanowires for On-Chip Powering of Autonomous Microsystems
- Enlight Renewable Energy Projects
- A New Strategy for Vibronic Spectroscopy of Radicals
- RodRadar: The End to Utility Strikes
